[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic-associated-diarrhea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic-associated-diarrhea":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100610966","evaluation-of-the-use-of-a-probiotic-containing-bifidobacterium-breve-prl2020-in-oral-drops-in-preventing-side-effects-from-amoxicillin-or-amoxicillinclavulanic-acid-antibiotic-use-100610966",false,"NCT07234448","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use: a Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Male and female participants aged 0-12 years.\n* Undergoing antibiotic therapy with amoxicillin or amoxicillin\u002Fclavulanic acid.\n* Parent or legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* Use of antibiotic therapy within 4 weeks prior to enrolment.\n* Use of other probiotic products or lactic acid bacteria during the study.\n* Pre-existing diarrhea within 4 weeks prior to enrolment.\n* Chronic inflammatory bowel disease.\n* Immunodeficiency.\n* Lack of parental or legal guardian consent to participate in the study.","ALL","0 Years","12 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 (Brevicillin® gocce) in preventing gastrointestinal side effects associated with antibiotic therapy using amoxicillin or amoxicillin\u002Fclavulanic acid in pediatric patients aged 0-12 years. Participants will be randomized 1:1 to receive either the probiotic supplement or placebo during standard antibiotic treatment for 6-10 days, followed by a post-treatment observation period up to day 15 without probiotic or placebo administration. The primary objective is to assess the reduction in the incidence of antibiotic-associated diarrhea (AAD).",[27],"Antibiotic-associated Diarrhea","NOT_YET_RECRUITING","2025-11-19",{"date":31,"type":32},"2025-11-24","ACTUAL",{"date":34,"type":21},"2025-12-01",{"date":36,"type":21},"2026-05-29",{"name":38,"class":39},"Liaquat University of Medical & Health Sciences","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100354490","rescue-fecal-microbiota-transplantation-for-national-refractory-intestinal-infections-100354490","NCT03895593","Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections","Rescue Fecal Microbiota Transplantation for Refractory Intestinal Infections: China National Registry","Inclusion Criteria: National patients with refractory intestinal infections receiving rescue FMT from the China Microbiota Transplantation System from September 2015 to December, 2029 will be included.\n\n\\-\n\nExclusion Criteria: Patients will be excluded from the analysis if they are not followed up for at least 12 weeks post-FMT.\n\n\\-",{"count":48,"type":21},100,"OBSERVATIONAL","A national data registry of patients receiving the rescue fecal microbiota transplantation for the refractory intestinal infections from the China Microbiota Transplantation System was designed to assess the short-term and long-term safety and efficacy.",[52,53,27],"Intestinal Infection","Clostridioides Difficile Infection",[55,56,57,27,58],"fecal microbiota transplantation","intestinal infection","clostridioides Difficile Infection","Washed microbiota transplantation","RECRUITING","2024-02-27",{"date":62,"type":32},"2024-02-29",{"date":64,"type":32},"2015-09-25",{"date":66,"type":21},"2029-05-01",{"name":68,"class":39},"The Second Hospital of Nanjing Medical University",1]